Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics.
To determine the anti-inflammatory actions of pranlukast, a cysteinyl leuklotriene receptor antagonist, we measured exhaled nitric oxide (NO) concentrations and eosinophil ratio in induced sputum of three groups of mild asthmatics (n = 30): treated with bronchodilators alone, with bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day), and bronchodilators and pranlukast (450 mg/day). Pranlukast (450 mg/day) reduced the eosinophil ratio in the induced sputum significantly (p < 0.01) without a major effect on the concentration of exhaled NO. Pranlukast also increased values of peak expiratory flow significantly (p < 0.05). Pranlukast may be useful for mild asthmatics, in part through its ability to suppress eosinophilic airway infiltration.
Yamauchi
K
K
The Third Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan.
Tanifuji
Y
Y
Pan
L H
LH
Yoshida
T
T
Sakurai
S
S
Goto
S
S
Kuroda
S
S
Kobayashi
H
H
Inoue
H
H
D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002867:Chromones / Q000627:therapeutic use*; D004804:Eosinophils; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D007958:Leukocyte Count; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
D002867:Chromones; D020024:Leukotriene Antagonists; C047681:pranlukast